Merck KGaA is investing $100 million in four manufacturing sites under a streamlining plan that also will result in the loss of four plants and 200 jobs.
Manufacturing has for the second time stepped on Ocular Therapeutix’s chance of an FDA approval for its new drug for pain following eye surgery.
With the expanding definition of “health” in play, does the category warrant a separate show in a program like the Lions?
AGC Asahi Glass, which bought CMC Biologics this year, will make its Seattle, Washington, area operation the headquarters of its drug business.
GlaxoSmithKline is nearing completion of its new manufacturing plant in India that will be able to crank out 8 billion tablets and 1 billion capsules a year.
Mylan and Biocon have hit a stumbling block that will delay potential approval of their biosimilar of Roche’s Herceptin in Europe.
Oxford BioMedica has a new deal for up to $100 million to provide the lentiviral vectors for the personalized CAR-T treatment Novartis is developing.
UAE-based Neopharma plans to build a $100 million plant in Abu Dhabi after recently picking up a plant in Japan.
CDMO Patheon is investing $45 million in four sites that stretch from the West Coast of the U.S. to Italy.
Facing persistent manufacturing difficulties, U.S.-based Pacira will stop producing chemo drug DepoCyt, laying off some employees in the process.
Roche is closing a plant in Massachusetts that makes cancer and blood screening tests and will lay off about 75 workers.